Creo technology is being adapted for use with robotic-assisted surgical platforms
The Programme allows Creo to explore the potential of our technology - introducing it to markets where it does not currently exist, and where it would be resource-intensive to do so alone.
By working with industry leaders on the development, optimisation or customisation of technology in relation to their needs and that of their industry, the Kamaptive Licensing Programme means our technology has the potential to reach thousands more patients worldwide.
